GU Cancers 2024 | How can radiotherapy make prostate cancer more immunogenic?

Sophia Kamran, MD, Massachusetts General Hospital, Boston, MA, comments on the disease biology of oligometastatic prostate cancer when treated with radiotherapy. Patients receiving stereotactic body radiotherapy (SBRT) were reported to have more immunogenic tumors post-treatment, leading to potential use of immune checkpoint inhibitors. Analysis of blood samples in patients revealed increased activation of CD4 cells. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.